CA-ANDERSEN-GLOBAL
21.7.2021 11:46:13 CEST | Business Wire | Pressemeddelelse
Andersen Global indgår en samarbejdsaftale med full service-advokatfirmaet IBRAHIM & PARTNERS i De Forenede Arabiske Emirater, hvilket tilføjer dimension og dækning til organisationens eksisterende kapaciteter gennem sine medlems- og samarbejdsfirmaer i regionen.
Med kontorer i Abu Dhabi og Dubai har IBRAHIM & PARTNERS en af de bedste praksisser inden for fusioner og opkøb i landet. Firmaet blev grundlagt i 2018 og ledes af administrerende partner Ahmed Ibrahim, som tidligere ledede fusioner og opkøb hos et af de største advokatfirmaer i både De Forenede Arabiske Emirater og Mellemøsten. Derudover blev Ahmed rangeret som en Band 1 Capital Markets-advokat af Chambers and Partners i 2021 og blev tidligere rangeret som Tier 1 Capital Markets-advokat af Legal 500 i 2018.
Firmaet er også konsekvent blevet anerkendt af Chambers and Partners , The Legal 500 og IFLR1000 , og dets eksperters ekspertise omfatter retssager, arbejdsret, bankvirksomhed og finans, privat billighedsret og fonde, olie og gas, byggeri, energi og skat. Deres kapitalmarkedsafdeling er et af de mest aktive kapitalmarkedsafdelinger i De Forenede Arabiske Emirater og har ledet næsten alle landets børsnoteringer og tegningsretsudstedelser, herunder to udstedere fra De Forenede Arabiske Emirater, der er noteret på London Stock Exchange.
”Vores kunder er trygge ved vores kombination af juridisk viden, kommercialitet og sektorbevidsthed, hvilket afspejles i de omfattende, innovative løsninger, som vores eksperter leverer,” sagde Ahmed. ”Samarbejdet med Andersen Global giver os mulighed for at betjene vores kunder med behov på tværs af flere retskredse på en sømløs måde, og positionerer vores firma yderligere som en sammenligningsorganisation, der sætter standarden for uovertrufne, skræddersyede løsninger i De Forenede Arabiske Emirater.”
“IBRAHIM & PARTNERS konkurrerer med nogle af de største advokatfirmaer regionalt, og deres tjenestetilbud vil give os mulighed for fortsat at tilbyde kunder et bredt spektrum af uafhængige, integrerede løsninger,” tilføjede bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz. ”Deres regionale fodaftryk og grænseoverskridende ekspertise styrker vores eksisterende platform, idet denne region fortsætter med at udvikle sig som et vigtigt globalt marked.”
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 8.000 eksperter globalt og er repræsenteret på mere end 280 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210721005448/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum